|
|
|
-
Monday, August 11, 2025
2:43:38 PM
|
|
 |
|
Everest Medicines Announces Full Approval of NEFECON(R) in Taiwan
Aug 11, 2025 07:37 HKT |  | | 云顶新耀耐赋康(R)扩产获批 亚洲全域完全批准双突破 加速迈向50亿销售峰值
Aug 08, 2025 18:09 HKT | | | 雲頂新耀耐賦康(R)擴產獲批 亞洲全域完全批准雙突破 加速邁向50億銷售峰值
Aug 08, 2025 18:09 HKT | | | 全球首个IgA肾病对因治疗药物耐赋康®扩产获批 云顶新耀加速提升可及性与产能布局
Aug 05, 2025 10:21 HKT | | | 全球首個IgA腎病對因治療藥物耐賦康®擴產獲批 雲頂新耀加速提升可及性與產能佈局
Aug 05, 2025 10:21 HKT | | | NEFECON(R) Receives NMPA Approval for Production Expansion in China,as Everest Medicines Accelerates Accessibility and Capacity Efforts
Aug 05, 2025 10:21 HKT | | | Everest Medicines Expands Strategic Investment in I-MAB to Advance the Global Value of Its Proprietary Next-Generation Cancer Immunotherapies
Aug 02, 2025 00:02 HKT | | | 雲頂新耀宣佈增加對I-Mab的戰略投資 開發自研新一代腫瘤免疫療法的全球價值
Aug 01, 2025 23:48 HKT | | | 云顶新耀宣布增加对I-Mab的战略投资 开发自研新一代肿瘤免疫疗法的全球价值
Aug 01, 2025 23:45 HKT | | | Biolog Enters the European Diagnostic Market, Bringing 45 Years of Anaerobic Culture Excellence
Jul 29, 2025 16:00 HKT |  | | China Medical System (867.HK, 8A8.SG) NDA for the Improved New Drug ZUNVEYL for Alzheimer's Disease Accepted in China
Jul 29, 2025 04:00 HKT |  | | 維立志博於聯交所主板成功上市
Jul 25, 2025 19:36 HKT |  | | 维立志博于联交所主板成功上市
Jul 25, 2025 18:00 HKT | | | 亿胜生物多剂量地夸磷索钠滴眼液获中国国家药品监督管理局批准上市
Jul 25, 2025 10:52 HKT |  | | 億勝生物多劑量地誇磷索鈉滴眼液獲中國國家藥品監督管理局批准上市
Jul 25, 2025 10:52 HKT | | | Multi-Dose Diquafosol Sodium Eye Drops Obtained Approval from NMPA for Commercialisation in China
Jul 25, 2025 10:52 HKT | | | 云顶新耀宣布配售股份 拟集资约15.725亿港元
Jul 25, 2025 10:01 HKT | | | 雲頂新耀宣布配售股份 擬集資約15.725億港元
Jul 25, 2025 10:01 HKT | | | Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million
Jul 25, 2025 10:01 HKT | | | 아반토코리아, 수원 사무실 광교중앙역 인근으로 이전
Jul 24, 2025 09:00 HKT |  | |
|
Next >>
|
|
|
| Copyright © 2025 ACN Newswire - Asia Corporate News Network |
|
|
Connect With us:
|
|